4 not yet recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 4 |
| Phase 1 | 2 | Not yet recruiting 2 |
Follow Efficacy: new trials by email Literature Review of Efficacy trials Research Report on Efficacy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells, Placebo - Spinal Cord Injury, Safety | Phase 2 | Not yet recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 60 | 2028-05-25 | 2025-11-25 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy - Efficacy | Phase 1 / Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 150 | 2024-10-01 | 2024-10-09 |
| Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency Niraparib - Efficacy | Phase 2 | Not yet recruiting | Korea University Anam Hospital | 33 | 2024-02-27 | 2024-02-01 |
Central Nervous System Diseases (1) · Nervous System Diseases (1) · Spinal Cord Diseases (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Injections (1) · Injections, Subcutaneous (1) · niraparib (1)
Hunan Province Tumor Hospital (1) · Korea University Anam Hospital (1) · Sichuan Huiyu Pharmaceutical Co., Ltd (1) · XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. (1)
China (1)